A Machine Learning Approach to Predicting Blood Glucose Levels for Diabetes Management
|
|
|
- Ashley Bailey
- 9 years ago
- Views:
Transcription
1 A Machine Learning Approach to Predicting Blood Glucose Levels for Diabetes Management Kevin Plis, Razvan Bunescu and Cindy Marling School of Electrical Engineering and Computer Science Russ College of Engineering and Technology Ohio University, Athens, Ohio 45701, USA Jay Shubrook and Frank Schwartz The Diabetes Institute Heritage College of Osteopathic Medicine Ohio University, Athens, Ohio 45701, USA Abstract Patients with diabetes must continually monitor their blood glucose levels and adjust insulin doses, striving to keep blood glucose levels as close to normal as possible. Blood glucose levels that deviate from the normal range can lead to serious short-term and long-term complications. An automatic prediction model that warned people of imminent changes in their blood glucose levels would enable them to take preventive action. In this paper, we describe a solution that uses a generic physiological model of blood glucose dynamics to generate informative features for a Support Vector Regression model that is trained on patient specific data. The new model outperforms diabetes experts at predicting blood glucose levels and could be used to anticipate almost a quarter of hypoglycemic events 30 minutes in advance. Although the corresponding precision is currently just 42%, most false alarms are in near-hypoglycemic regions and therefore patients responding to these hypoglycemia alerts would not be harmed by intervention. Introduction and Motivation Of the world s 347 million people with diabetes, from 5 to 10% have type 1 diabetes (T1D), the most severe kind. In T1D, the pancreas fails to produce insulin, an essential hormone needed to convert food into energy and to regulate blood glucose (BG) levels. T1D can not be prevented or cured, but it can be effectively treated with external supplies of insulin and managed through BG control. Good BG control helps to delay or prevent serious long-term complications of diabetes (Diabetes Control and Complications Trial Research Group 1993). Patients strive to avoid both hyperglycemia, or high BG levels, and hypoglycemia, or low BG levels. Hyperglycemia can lead to long-term complications including blindness, amputations, kidney failure, strokes, and heart attacks, while hypoglycemia can cause immediate symptoms of weakness, confusion, dizziness, sweating, shaking, and, if not treated in time, seizures, coma or death. Achieving and maintaining good BG control is a difficult task. T1D patients must monitor their BG levels throughout the day and take corrective action whenever they are hyper Copyright c 2014, Association for the Advancement of Artificial Intelligence ( All rights reserved. or hypoglycemic. Being able to accurately predict impending hyper or hypoglycemia would give patients time to intervene and prevent these BG excursions, improving overall health, safety, and quality of life. Such predictions would enable or facilitate numerous potential applications of benefit to T1D patients, including: (a) alerts warning of immediately impending problems; (b) recommendations of interventions to prevent problems; (c) what if analysis to project the effects of different lifestyle choices and treatment options; and (d) enhanced individual BG profiles that could help physicians tailor treatment to the needs of each patient. There has been a recent explosion of interest in BG prediction due to its role in closed loop control for the Artificial Pancreas Project (Juvenile Diabetes Research Foundation 2014). In brief, an artificial pancreas consists of three components: an insulin pump; a continuous BG monitoring system; and a closed loop control algorithm to tie them together, so that insulin flow can be continuously adjusted to meet patient needs (Klonoff 2007; Dassau et al. 2012). Although still a work in progress, Time Magazine named the artificial pancreas one of the 25 best inventions of 2013 (Time Magazine 2013). Several recent publications detail related work in BG prediction (Jensen et al. 2013; Zecchin et al. 2013; Wang et al. 2014); however, a limiting factor has been the use of small and/or simulated patient datasets. Over the past ten years, we have worked on intelligent decision support systems for patients with T1D on insulin pump therapy (Marling et al. 2012), and we have amassed a database of over 1,600 days worth of clinical patient data. We are now capitalizing on this data to build machine learning models aimed at predicting BG levels 30 and 60 minutes into the future. Since BG measurements have a natural temporal ordering, we approach the task of predicting BG levels as a time series forecasting problem. The collected data consists of blood glucose measurements, taken at fiveminute intervals through a continuous glucose monitoring (CGM) system, and the corresponding daily events that impact BG levels, such as insulin, meals, exercise and sleep. In this paper, we describe our machine learning approach and report on our latest experiments, which focus on the safetycritical problem of predicting hypoglycemia. The structure of the paper is as follows: we first introduce a small dataset on which we assess the prediction performance of diabetes experts; we then describe a physiological model that is used
2 to generate informative features for a support vector regressor; in the following experimental results section we evaluate the performance of the new model, both on the general blood glucose level prediction and on the more focused task of hypoglycemic event prediction; the paper ends with conclusions and ideas for future work. Blood Glucose Prediction Dataset Using data collected from 5 T1D patients, we created an evaluation dataset of 200 timestamps, 40 points per patient, with the aim of measuring the prediction performance of expert physicians. The 200 evaluation points were manually selected to reflect the diverse set of situations the predictor would encounter in practice: different times of day or night; close to or far from each of the possible types of daily events; on rising, decreasing, or flat BG curves; close to or far from local minima or maxima of the BG curve where the local optima were either in the past or in the future; or in the vicinity of inflection points. To better understand the role of daily events in the dynamics of blood glucose levels, we asked three diabetes experts to label this evaluation dataset with their 30 and 60 minute predictions. The annotation exercise was performed using an in-house graphical user interface (GUI) through which the doctors could see only the patient data up to the present time t 0. The doctors were able to use the interface to navigate to any day in the past in order to make generalizations about BG level behavior. Before each annotation exercise, the doctors were trained to use the annotation user interface on a separate development dataset of ten points. For each point t 0 in the dataset, the doctors made two predictions: one for 30 minutes, one for 60 minutes, in this order. After the two predictions were made for any given point, the system displayed the real BG behavior, so that the doctors could further fine tune their prediction strategy. The dataset annotation was done separately with each of the three doctors. The root mean square error (RMSE) results of the three physicians are summarized in Table 1, together with the performances of two baselines on the same dataset of 200 timestamps. The first baseline, t 0, simply assumes that BG does not change, i.e., stays at its t 0 level. The second is an Auto Regressive Integrated Moving Average (ARIMA) (Box, Jenkins, and Reinsel 2008) trained on 4 days of CGM data an exploratory data analysis had shown that 4 days gave the lowest RMSE for the ARIMA model. Model identification for ARIMA was completed with the R statistical function auto.arima, which uses the Bayes information criterion to determine the orders p and q of the autoregressive and moving average components, and the Phillips-Perron unit root test for determining the order d of the difference component. The best performing doctors outperform the simple t 0 baseline. Most important, however, is the comparison between the doctors and ARIMA. Our highest scoring doctors, who use both the CGM data and daily events to perform prediction, outperform the ARIMA model that is using only CGM data. Regarding the third doctor s performance, we noticed during the annotation sessions that the doctor was fairly accurate in guessing the trend of the BG levels, but Table 1: Physician prediction RMSE vs. baselines. Horizon t 0 ARIMA Phys 1 Phys 2 Phys 3 30 min min Table 2: Physician prediction cost vs. baselines. Horizon t 0 ARIMA Phys 1 Phys 2 Phys 3 30 min min typically overestimated the magnitude of the increase or decrease in BG levels. To quantify this behavior, we defined a ternary classification task with the following three classes: 1. Same (S): the future BG value is within a threshold τ of the current value. 2. Lower (L): the future BG value is more than τ lower than the current value. 3. Higher (H): the future BG value is more than τ higher than the current value. We used a threshold τ = 5mg/dl for 30 minute prediction and τ = 10mg/dl for 60 minute prediction. We then evaluated performance using a symmetric cost matrix C with a zero diagonal in which C(L, S) = 0.5, C(H, S) = 0.5, and C(L, H) = 1. The average costs for each doctor over the same evaluation dataset are listed in Table 2. While the first physician still obtains the best results (lowest costs), the third physician now has results on the 60 minute task that are better than the baselines and the second physician. Additional support for the utility of daily event data came from the live feedback that the doctors generated during the annotation sessions. In making their predictions, the doctors would regularly refer to the presence of daily events and their properties, such as: the timing of meal events, the number of carbohydrates and meal composition, the frequency of the bolus events and their type and dosage. This further reinforced our belief that daily event data is important in BG prediction, motivating us to explore the utility of physiological models in the extraction of informative features for an adaptive regression model. Physiological Model Physiological models try to capture the dynamics of glucose relevant variables within different systems in the body. For example, equations have been introduced in the literature for tracking the carbohydrate intake as it is converted to blood glucose which then interacts with the kidneys, liver, muscles, and other body systems. Most physiological models characterize the overall dynamics into three compartments: meal absorption dynamics, insulin dynamics, and glucose dynamics (Andreassen et al. 1994; Lehmann and Deutsch 1998; Briegel and Tresp 2002). Since they are based on the same data, the equations used in the literature to model the
3 Figure 1: Variables and dependencies in the physio model. underlying processes are almost identical (Briegel and Tresp 2002; Duke 2009). For our physiological model, we used these equations based on the description in Duke s PhD thesis (Duke 2009), with a few adaptations in order to better match published data and feedback from our doctors. A physiological model of glucose dynamics can be seen as a continuous dynamic model that is described by its state variables X, input variables U, and a state transition function that computes the next state given the current state and input variables i.e. X t+1 = f(x t, U t ). The vector of state variables X is organized according to the three compartments as follows: 1. Meal Absorption Dynamics: C g1 (t) = carbohydrate consumption (g). C g2 (t) = carbohydrate digestion (g). 2. Insulin Dynamics: I S (t) = subcutaneous insulin (µu). I m (t) = insulin mass (µu). I(t) = level of active plasma insulin (µu/ml). 3. Glucose Dynamics: G m (t) = blood glucose mass (mg). G(t) = blood glucose concentration (mg/dl). The vector of input variables U contains the carbohydrate intake U C (t), measured in grams (g), and the amount of rapid acting insulin U I (t), measured in insulin units (U). The value U I (t) at any time step t is computed automatically from bolus and basal rate information. The state transition function captures dependencies among variables in the model, as illustrated in Figure 1. The state transition equations are parameterized with a set of parameters α and are listed below for each compartment. For the meal absorption compartment, the equations are: C g1 (t + 1) = C g1 (t) α 1C C g1 (t) + U C(t) [consumption] C g2 (t + 1) = C g2 (t) + α 1C C g1 (t) α 2C/(1 + 25/C g2 (t)) [digestion] The equations for the insulin compartment are: I S(t + 1) = I S(t) α fi I S(t) + U I(t) [injection] I m(t + 1) = I m(t) + α fi I S(t) α ci I m(t) [absorption] The general equation for the glucose compartment is G m(t+1)=g m(t)+ abs ind dep clr + egp, where: abs = α 3C α 2C/(1 + 25/C g2 (t)) [absorption] ind = α 1ind G(t) [insulin independent utilization] dep = α 1dep I(t) (G(t) + α 2dep )[insulin dependent utilization] clr = α 1clr (G(t) 115) [renal clearance, only when G(t) > 115)] egp = α 2egp exp( I(t)/α 3egp) α 1egp G(t) [endogenous liver production] Finally, the glucose and insulin concentrations depend deterministically on their mass equivalents as follows, where bm refers to the body mass and IS refers to the insulin sensitivity: G(t) = G m(t)/(2.2 bm) I(t) = I m(t) IS/(142 bm) The parameters α used in the physiological model were tuned to match published behavior and further refined based on feedback from the doctors, who were shown plots of the dependencies between variables in the model. In order to account for the noise inherent in the CGM data and the input variables, the state transition equations were used in an extended Kalman filter (EKF) model (Simon 2006), as described in more detail in (Bunescu et al. 2013). SVR Model with Physiological Features The state vector computed by the physiological model is X(t) = [C g1 (t), C g2 (t), I S (t), I m (t), I(t), G m (t), G(t)]. While the transition equations reflect generic blood glucose behavior, the actual parameters of these equations differ among patients. Instead of tuning these parameters directly for each patient, we opted for a simpler approach, using the state variables to create features for a Support Vector Regression (SVR) model (Smola and Scholkopf 1998) that was individualized for each patient, as follows. First, the extended Kalman filter was run up to the training/test point t 0, with a correction step every 5 minutes, including a correction at t 0. This resulted in a state vector X(t 0 ). The EKF model was then run in prediction mode for 60 more minutes, and the state vectors at 30 minutes X(t ) and 60 minutes X(t ) were selected for feature generation. The actual physiological features were as follows: all the state variables in the vectors X(t ), X(t ), and the difference vectors X(t ) X(t 0 ), X(t ) X(t 0 ). The 4 * 7 = 28 physiological features were augmented with a set of 12 i features that were meant to encode information about the trend of the CGM plot in the hour before the test point t 0. Each i feature was computed as the difference between the BG level at time t 0 and the BG level at i time steps in the past, i.e., i = BG(t 0 ) BG(t 0 5i). Furthermore, whenever ARIMA was used to generate features, it was trained on the 4 days before t 0 and then used to forecast the 12 values at 5 minute intervals in the hour after t 0. These values were used as additional features in one version of the SVR system. For a given test point t 0 in the dataset, the SVR systems were trained on the week of data preceding t 0, using a Gaussian kernel. The width γ of the kernel, the width ɛ of the ɛ-insensitive tube, and the capacity parameter C were tuned using grid search on the data preceding the training week.
4 Table 3: SVR prediction results vs. baselines and highest scoring doctor results. Horizon t 0 ARIMA Phys 1 SVRφ SVRφ+A 30 min min Experimental Results We used the evaluation dataset previously described to compare the following BG prediction systems: 1. ARIMA and the simple t 0 baseline. 2. The SVR system that uses physiological features, as described above. Two versions of this system were evaluated: with (SVRφ+A) and without (SVRφ) ARIMA features. The RMSE results are summarized in Table 3, in which, for comparison purposes, we repeat the first three columns of results from Table 1. The new SVR system that is trained with physiological features outperforms the t 0 and ARIMA baselines. Most importantly, it also outperforms the best predictions from our three diabetes experts, thus demonstrating the utility of physiological modeling for the engineering of features in machine learning models for blood glucose level prediction. To determine whether the overall competitive RMSE performance can translate to practical utility, we conducted an evaluation of the SVR system on the more focused task of hypoglycemia prediction, as described in the next section. Hypoglycemia Prediction Hypoglycemia prediction is the most critical application of BG prediction from a clinical perspective. Untreated hypoglycemia is a safety hazard for patients, especially for sleeping patients, who are at risk for the dead in bed syndrome. Being able to accurately predict that BG will drop to under 70 mg/dl 30 minutes in advance would give patients time to intervene and prevent the drop. The evaluation dataset described above contains 200 evaluation points, of which only 13 belong to hypoglycemic regions. In order to estimate the system s performance on predicting hypoglycemia, we constructed a much larger dataset of 5,816 test points as follows. First, consecutive CGM readings under 70 mg/dl were combined into hypo events. Events that lasted less than 20 minutes, i.e., had 3 or fewer sensor readings, were ignored. The remaining hypo events were checked for errors that might suggest recent sensor failure, such as missing data shortly before or after the event. For each hypo event, a prediction time t 0 was selected such that t was the first point where blood glucose dropped below 70. This resulted in 152 hypo events and corresponding prediction times. A set of non-hypo points was then sampled automatically such that the overall evaluation dataset contains a mix of hypo and non-hypo points reflecting the true distribution. First, the ratio of hypo to non-hypo read- Table 4: SVR vs. ARIMA performance on hypo prediction. System TPR FPR P F 1 SVR 23.0% 0.8% 42.7% 29.9% ARIMA 9.9% 0.3% 44.1% 16.2% Table 5: SVR vs. ARIMA vs. t 0 performance. RMSE Average Cost System All 30m 60m 30m 60m SVR ARIMA t ings was calculated for each patient. Then, the corresponding number of non-hypo points for that patient was sampled at random from the patient s CGM data. For example, if a patient had 64 hypo events and the ratio of non-hypo to hypo points was 25 to 1, then 1600 non-hypo points were selected at random from the patient s CGM history. Each sampled point was checked to make sure that the BG level did not fall under 70 mg/dl in the next hour. This procedure resulted in a new evaluation dataset of 5,816 test points. During evaluation, each of the 5,816 test points served as the prediction time t 0. The SVR system was trained on data preceding time t 0, and predictions were made for future timestamps in 5 minute increments, from t to t If any one of the 12 predictions was less than 70 mg/dl, the system was considered to have predicted a hypo event. Otherwise, the system was considered to have predicted a nonhypo event. Table 4 shows the SVR and ARIMA results on the task of predicting hypoglycemic events, in terms of sensitivity/recall (TPR), 1 specificity (FPR), precision (P), and F-measure (F 1 ). By definition, the baseline t 0 would never predict hypoglycemia; therefore, it is not shown in this table. Table 5 compares the SVR system with the ARIMA and t 0 baselines in terms of their RMSE and average ternary classification costs at 30 and 60 minutes. The results in Table 4 show that the SVR system is able to predict 23% of the hypoglycemic events with a false positive rate under 1%. All 47 false positives were for BG readings under 140 mg/dl, with 32 of them for near-hypoglycemic readings of 80 mg/dl or lower. Were the model to be used in practice, patients responding to hypoglycemia alerts at these BG levels would not be harmed by intervention. While we are still working to improve sensitivity, results to date provide proof of concept that the system could alert patients to impending dangerous situations. Conclusion We have described a machine learning approach to predicting blood glucose levels and presented the results of recent experiments in hypoglycemia prediction. An SVR model, informed by a physiological model and trained on patient specific data, has outperformed diabetes experts at
5 predicting blood glucose levels and can predict 23% of hypoglycemic events 30 minutes in advance. We are working to improve the overall accuracy of our model and its sensitivity to impending hypoglycemia, in part through incorporating additional daily events that impact blood glucose levels into the model. For example, sleep is known to impact blood glucose levels, but it is not factored into current physiological models. Our database includes patient-entered sleep records which we are now incorporating. Further, we are experimenting with newly available, low-cost, noninvasive and unobtrusive physiological sensors to aid in the automated identification of relevant daily events. Diabetes management presents many opportunities for clinicians and artificial intelligence researchers to collaborate on challenging research that could potentially improve health, safety and quality of life for millions of people living with diabetes. Acknowledgments This material is based upon work supported by the National Science Foundation under Grant No We gratefully acknowledge additional support from Medtronic and Ohio University. We also thank our past and present graduate research assistants, research nurses, and over 50 anonymous T1D patients for their contributions to this work. References Andreassen, S.; Benn, J. J.; Hovorka, R.; Olesen, K. G.; and Carson, E. R A probabilistic approach to glucose prediction and insulin dose adjustment: Description of metabolic model and pilot evaluation study. Computer Methods and Programs in Biomedicine 41: Box, G. E. P.; Jenkins, G. M.; and Reinsel, G. C Time Series Analysis: Forecasting and Control, 4th Edition. Wiley. Briegel, T., and Tresp, V A nonlinear state space model for the blood glucose metabolism of a diabetic. Automatisierungstechnik 50: Bunescu, R.; Struble, N.; Marling, C.; Shubrook, J.; and Schwartz, F Blood glucose level prediction using physiological models and support vector regression. In Proceedings of the IEEE 12th International Conference on Machine Learning and Applications (ICMLA). Miami, FL: IEEE. Dassau, E.; Lowe, C.; Barr, C.; Atlas, E.; and Phillip, M Closing the loop. International Journal of Clinical Practice 66: Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329(14): Duke, D. L Intelligent Diabetes Assistant: A Telemedicine System for Modeling and Managing Blood Glucose. Ph.D. Dissertation, Carnegie Mellon University, Pittsburgh, Pennsylvania. Jensen, M. H.; Christensen, T. F.; Tarnow, L.; Seto, E.; Johansen, M. D.; and Hejlesen, O. K Real-time hypoglycemia detection from continuous glucose monitoring data of subjects with type 1 diabetes. Diabetes Technology and Therapeutics 15(7). Juvenile Diabetes Research Foundation Artificial pancreas project research. accessed April, Klonoff, D. C The artificial pancreas: How sweet engineering will solve bitter problems. Journal of Diabetes Science and Technology 1(1): Lehmann, E., and Deutsch, T Compartmental models for glycaemic prediction and decision-support in clinical diabetes care: promise and reality. Computer Methods and Programs in Biomedicine 56: Marling, C.; Wiley, M.; Bunescu, R. C.; Shubrook, J.; and Schwartz, F Emerging applications for intelligent diabetes management. AI Magazine 33(2): Simon, D Optimal State Estimation: Kalman, H Infinity, and Nonlinear Approaches. Wiley. Smola, A. J., and Scholkopf, B A tutorial on support vector regression. Technical report, NeuroCOLT2 Technical Report Series. Time Magazine The 25 best inventions of the year accessed April, Wang, Q.; Molenaar, P.; Harsh, S.; Freeman, K.; Xie, J.; Gold, C.; Rovine, M.; and Ulbrecht, J Personalized state-space modeling of glucose dynamics for type 1 diabetes using continuously monitored glucose, insulin dose, and meal intake: An extended kalman filter approach. Journal of Diabetes Science and Technology 8(2): Zecchin, C.; Facchinetti, A.; Sparacino, G.; and Cobelli, C Reduction of number and duration of hypoglycemic events by glucose prediction methods: A proof-of-concept in silico study. Diabetes Technology & Therapeutics 15(1):66 77.
Insulin dosage based on risk index of Postprandial Hypo- and Hyperglycemia in Type 1 Diabetes Mellitus with uncertain parameters and food intake
based on risk index of Postprandial Hypo- and Hyperglycemia in Type 1 Diabetes Mellitus with uncertain parameters and food intake Remei Calm 1, Maira García-Jaramillo 1, Jorge Bondia 2, Josep Vehí 1 1
A Fuzzy Controller for Blood Glucose-Insulin System
Journal of Signal and Information Processing, 213, 4, 111-117 http://dx.doi.org/1.4236/jsip.213.4215 Published Online May 213 (http://www.scirp.org/journal/jsip) 111 Ahmed Y. Ben Sasi 1, Mahmud A. Elmalki
I HAVE JUST BEEN DIAGNOSED WITH TYPE 1 DIABETES
Dominika In better control with her pump since 2012 I HAVE JUST BEEN DIAGNOSED WITH TYPE 1 DIABETES The diagnosis of Type 1 diabetes may come as a shock and may lead to many questions, such as: Why is
A guidebook for people with diabetes
A guidebook for people with diabetes This booklet is designed to supplement, not replace, your doctor s advice. Please consult your doctor if you have any questions about what you read. You ll learn how
Type 1 Diabetes - Managing a Critical Ratio
Objectives Students will learn about how ratios and proportions are a key part of managing Type 1 Diabetes Students will learn about the regulation of blood glucose through insulin (hormone) binding with
DIABETIC EDUCATION MODULE ONE GENERAL OVERVIEW OF TREATMENT AND SAFETY
DIABETIC EDUCATION MODULE ONE GENERAL OVERVIEW OF TREATMENT AND SAFETY First Edition September 17, 1997 Kevin King R.N., B.S., C.C.R.N. Gregg Kunder R.N., B.S.N., C.C.T.C. 77-120 CHS UCLA Medical Center
Alternative method for delivering insulin using continuous subcutaneous insulin infusion (CSII) open loop system
ISHP Spring CE Conference April 12, 2015 St. Luke s Medical Center Randi Lynn Griffiths, PharmD Clinical outpatient pharmacist Boise VA Medical Center Boise, Idaho Alternative method for delivering insulin
AN INTELLIGENT SUPPORT SYSTEM FOR DIABETIC PATIENTS
AN INTELLIGENT SUPPORT SYSTEM FOR DIABETIC PATIENTS Mark Hoogendoorn, Michel C. A. Klein, Nataliya M. Mogles VU University Amsterdam, Department of Artificial Intelligence, De Boelelaan 1081, Amsterdam,
2. What Should Advocates Know About Diabetes? O
2. What Should Advocates Know About Diabetes? O ften a school district s failure to properly address the needs of a student with diabetes is due not to bad faith, but to ignorance or a lack of accurate
Causes, incidence, and risk factors
Causes, incidence, and risk factors Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both. To understand diabetes,
Self-tuning Insulin Adjustment Algorithm for Type I Diabetic Patients Based on Multi-Doses Regime.
International Simposium on Robotics and Automation 24 August 25-27, 24 Self-tuning Adjustment Algorithm for Type I Diabetic Patients Based on Multi-Doses Regime. D.U. Campos-Delgado Facultad de Ciencias
Diabetes and Technology. Disclosures Certified Insulin Pump Trainer for: Animas Medtronic Diabetes Omnipod. Rebecca Ray, MSN, APRN, FNP-C
Diabetes and Technology Rebecca Ray, MSN, APRN, FNP-C Insulin Pump Therapy and Continuous Glucose Monitoring In Patients with Type 2 Diabetes Page 1 Disclosures Certified Insulin Pump Trainer for: Animas
Title: Using Formal Methods to Improve Safety of Home-Use Medical Devices
Title: Using Formal Methods to Improve Safety of Home-Use Medical Devices Authors: Ayan Banerjee Impact Lab, Arizona State University [email protected] Yi Zhang Center for Devices and Radiological Health,
Artificial Neural Network Algorithm for On-Line Glucose Prediction from Continuous Glucose Monitoring
Artificial Neural Network Algorithm for On-Line Glucose Prediction from Continuous Glucose Monitoring C. Pérez-Gandía 1 ' 2, A. Facchinetti 3, G. Sparacino 3, C. Cobelli 3, E.J. Gómez 2 ' 1, M. Rigla 4,
The Burden Of Diabetes And The Promise Of Biomedical Research
The Burden Of Diabetes And The Promise Of Biomedical Research Presented by John Anderson, MD Incoming Chair, ADA s National Advocacy Committee; Frist Clinic, Nashville, TN Type 1 Diabetes Usually diagnosed
Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.
Diabetes Definition Diabetes is a chronic (lifelong) disease marked by high levels of sugar in the blood. Causes Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused
WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES?
Christian In better control with his pump since 2012 WHAT CAN I DO TO REDUCE MY RISK OF DEVELOPING THE COMPLICATIONS OF TYPE 1 DIABETES? Many people with Type 1 diabetes worry about potential long-term
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
A Reference Guide for School Nurses. with the Medtronic MiniMed Insulin Pump
A Reference Guide for School Nurses with the Medtronic MiniMed Insulin Pump Table Of Contents I Table of Contents The Medtronic MiniMed Insulin Pump A Reference Guide for School Nurses For the 522, 722,
Continuous Glucose Monitoring Sensor:
Federal Budget Submission 2016-2017 Continuous Glucose Monitoring Sensor: the need to invest in type 1 diabetes Medtronic Australasia Pty Ltd January 2016 Medtronic Australasia Pty Ltd Submission to the
Diabetes. Emergency Checklists. From A Child in Your Care Has Diabetes. A Collection of Information. Copyright 2005 by Elisa Hendel, M.Ed.
Diabetes Emergency Checklists From A Child in Your Care Has Diabetes. A Collection of Information. Copyright 2005 by Elisa Hendel, M.Ed. Hyperglycemia High Blood Sugar * Hyperglycemia occurs when the blood
Imagine a world... Believe in better control. MiniMed Veo Paradigm System
Imagine a world... Believe in better control MiniMed Veo Paradigm System 1 Imagine a world... Where you can exercise whenever you want and not have to carb load or worry about hypos. R Where you can eat
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Haidar A, Legault L, Matteau-Pelletier L, et
Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes NATIONAL DIABETES INFORMATION CLEARINGHOUSE
NATIONAL DIABETES INFORMATION CLEARINGHOUSE Am I at Risk for type 2 Diabetes? Taking Steps to Lower the Risk of Getting Diabetes U.S. Department of Health and Human Services National Institutes of Health
Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus
Insulin Pump Therapy and Continuous Glucose Sensor Use in the Management of Diabetes Mellitus Louis Haenel, IV, DO, FACOI, FACE Endocrinology Roper Hospital Charleston, SC Dr. Louis Haenel IV has disclosed
Imagine a world... Believe in better control. MiniMed Veo Paradigm System Questions and Answers About Insulin Pumping
Imagine a world... Believe in better control MiniMed Veo Paradigm System Questions and Answers About Insulin Pumping 1 Imagine a world... Where you can exercise whenever you want and not have to carb load
Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro
PRESS RELEASE Adocia reports positive results from phase IIa clinical study of ultra-fast acting BioChaperone Lispro BioChaperone Lispro is significantly faster than Humalog in type I diabetic patients;
Introduction. We hope this guide will aide you and your staff in creating a safe and supportive environment for your students challenged by diabetes.
Introduction Diabetes is a chronic disease that affects the body s ability to metabolize food. The body converts much of the food we eat into glucose, the body s main source of energy. Glucose is carried
Sponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
LESSON TWO: COMPARE AND CONTRAST TYPE 1 AND TYPE 2 DIABETES
LESSON TWO: COMPARE AND CONTRAST TYPE 1 AND TYPE 2 DIABETES FOCUS: Students will be given information on the two major types of diabetes, and they will analyze how the two types compare and contrast. OBJECTIVES:
X-Plain Hypoglycemia Reference Summary
X-Plain Hypoglycemia Reference Summary Introduction Hypoglycemia is a condition that causes blood sugar level to drop dangerously low. It mostly shows up in diabetic patients who take insulin. When recognized
HOW TO CARE FOR A PATIENT WITH DIABETES
HOW TO CARE FOR A PATIENT WITH DIABETES INTRODUCTION Diabetes is one of the most common diseases in the United States, and diabetes is a disease that affects the way the body handles blood sugar. Approximately
Department Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage.
Department Of Biochemistry Subject: Diabetes Mellitus Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage. Diabetes mellitus : Type 1 & Type 2 What is diabestes mellitus?
Type 1 Diabetes. Pennington Nutrition Series. Overview. About Insulin
Pennington Nutrition Series Healthier lives through education in nutrition and preventive medicine Pub No. 32 Type 1 Diabetes Overview Type 1 Diabetes (DM) is usually diagnosed in children and young adults.
Diabetes mellitus 1 عبد هللا الزعبي. pharmacology. Shatha Khalil Shahwan. 1 P a g e
Diabetes mellitus 1 pharmacology عبد هللا الزعبي 1 P a g e 4 Shatha Khalil Shahwan Diabetes mellitus The goals of the treatment of diabetes 1. Treating symptoms 2. Treating and Preventing acute complications
BOLUS INSULIN DOSAGES H. Peter Chase, MD and Erin Cobry, BS
CHAPTER 6: BOLUS INSULIN DOSAGES H. Peter Chase, MD and Erin Cobry, BS WHAT IS BOLUS INSULIN? Bolus insulin dosages refer to the quick bursts of insulin given to cover the carbohydrates in meals or snacks
Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES. Historical Perspective. Insulin Pumps in Pregnancy. Insulin Pumps in the US
Objectives PERINATAL INSULIN PUMPS: BASICS FOR NURSES Jo M. Kendrick, APN BC, CDE [email protected] Describe indications and contraindications for insulin pump use in hospitalized patients Differentiate
How to get the most of your blood glucose readings
How to get the most of your blood glucose readings Page 3 Page 4 Page 5 Page 5 Page 7 Page 7 Page 8 Page 9 Page 10 Page 11 1 Why you should do blood glucose monitoring? 2 How to do it correctly? 3 Who
A Comparative Study of the Pickup Method and its Variations Using a Simulated Hotel Reservation Data
A Comparative Study of the Pickup Method and its Variations Using a Simulated Hotel Reservation Data Athanasius Zakhary, Neamat El Gayar Faculty of Computers and Information Cairo University, Giza, Egypt
Inpatient Treatment of Diabetes
Inpatient Treatment of Diabetes Alan J. Conrad, MD Medical Director Diabetes Services EVP, Physician Alignment Diabetes Symposium November 12, 2015 Objectives Explain Palomar Health goals for inpatient
X-Plain Diabetes - Introduction Reference Summary
X-Plain Diabetes - Introduction Reference Summary Introduction Diabetes is a disease that affects millions of Americans every year. Your doctor may have informed you that you have diabetes. Although there
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What
Diabetes Monitoring Diary
Diabetes Monitoring Diary For those Counting Diabetes Service My targets: Before breakfast Before other meals Before bed... mmol/l... mmol/l... mmol/l Correcting high blood glucose levels: Information
Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control. Linda Macdonald, M.D. November 19, 2008
Monitoring and Carbohydrate Counting: The Cornerstones of Diabetes Control Linda Macdonald, M.D. November 19, 2008 Objectives Understand the relationship between insulin, carbohydrate intake, and blood
Statistical Learning for Short-Term Photovoltaic Power Predictions
Statistical Learning for Short-Term Photovoltaic Power Predictions Björn Wolff 1, Elke Lorenz 2, Oliver Kramer 1 1 Department of Computing Science 2 Institute of Physics, Energy and Semiconductor Research
An Improved PID Switching Control Strategy for Type 1 Diabetes
An Improved PID Switching Control Strategy for Type 1 Diabetes Gianni Marchetti, Massimiliano Barolo, Lois Jovanovic, Howard Zisser, and Dale E. Seborg, Member, IEEE Department of Chemical Engineering
How to design an insulin pump
How to design an insulin pump Learn about the purpose of an insulin pump, its overall workings, and the requirements needed for its design as well as implementation. By Asha Ganesan Applications Engineer
Design of an Insulin Pump. Purpose of an Insulin Pump:
Design of an Insulin Pump Purpose of an Insulin Pump: Insulin is a hormone central to regulating carbohydrate and fat metabolism in the body. It is secreted regularly within the body and aids in converting
tips Insulin Pump Users 1 Early detection of insulin deprivation in continuous subcutaneous 2 Population Study of Pediatric Ketoacidosis in Sweden:
tips Top International Publications Selection Insulin Pump Users Early detection of insulin deprivation in continuous subcutaneous insulin infusion-treated Patients with TD Population Study of Pediatric
Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Support Supplement
CLINICALLY T E S T E D Natural Blood Sugar Metabolic Syndrome with Prediabetic Factors Clinical Study Summary Concerning the Efficacy of the GC Control Natural Blood Sugar Metabolic Syndrome with Prediabetic
Insulin Dose Adjustment REAL-Time CGMS Guidelines for Subjects on Pump Therapy
Insulin Dose Adjustment REAL-Time CGMS Guidelines for Subjects on Pump Therapy In addition to using the blood sugar logs to adjust your insulin doses every week, you should also use your continuous glucose
The Economic Impact and Cost-Effectiveness of Glucose Monitoring
The Economic Impact and Cost-Effectiveness of Glucose Monitoring William H. Herman, MD, MPH Stefan S. Fajans/GlaxoSmithKline Professor of Diabetes Professor of Internal Medicine and Epidemiology University
Basal Rate Testing Blood sugar is affected at any time by 1) basal insulin 2) food (carbohydrate) intake 3) bolus insulin (meal time and correction)
Basal Rate Testing Blood sugar is affected at any time by 1) basal insulin 2) food (carbohydrate) intake 3) bolus insulin (meal time and correction) 4) activity and 5) other factors such as stress and
Forecasting of Economic Quantities using Fuzzy Autoregressive Model and Fuzzy Neural Network
Forecasting of Economic Quantities using Fuzzy Autoregressive Model and Fuzzy Neural Network Dušan Marček 1 Abstract Most models for the time series of stock prices have centered on autoregressive (AR)
Methods for Delivering Insulin and Monitoring Blood Sugar. A Review of the Research for Children, Teens, and Adults With Diabetes
Methods for Delivering Insulin and Monitoring Blood Sugar A Review of the Research for Children, Teens, and Adults With Diabetes Is This Information Right for Me? Yes, if: Your doctor* has told you that
System Aware Cyber Security
System Aware Cyber Security Application of Dynamic System Models and State Estimation Technology to the Cyber Security of Physical Systems Barry M. Horowitz, Kate Pierce University of Virginia April, 2012
Algorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
Diabetes Education Information for Teachers and School staff
Diabetes Education Information for Teachers and School staff The information below is intended to educate school staff on the basics of diabetes care. If you have a student in your classroom or you will
Diabetes Insulin Pump Health Care Plan District Nurse Phone: 262-560-2104 District Nurse Fax: 262-560-2106
EMPOW ERING A COMMUNITY OF LEARNERS AND LEADERS Diabetes Insulin Pump Health Care Plan District Nurse Phone: 262-560-2104 District Nurse Fax: 262-560-2106 Student DOB School Grade Doctor Phone School Year
Module I October 18-22, 2015 JW Marriott Marquis Hotel, Dubai, UAE
CME Accreditation is under process Module 1: Diabetes Facts and Diabetes in the Clinic Module 2: Nursing theory and educational (pedagogical) tools to advise and educate people with diabetes and their
Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University
Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die
Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks
Background: Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks Final Background and Scope November 19, 2015 The Centers for Disease Control
Health Professional s. Guide to INSULIN PUMP THERAPY
Health Professional s Guide to INSULIN PUMP THERAPY Table of Contents Introduction Presenting Insulin Pump Therapy to Your Patients When Your Patient Chooses the Pump Estimates for Starting Insulin Pump
Insulin Pump Management and Continuous Glucose Monitoring Systems (CGMS)
Insulin Pump Management and Continuous Glucose Monitoring Systems (CGMS) Faith Daily, RN, BSN, CDE, CPT Certified Diabetes Educator/Insulin Pump Trainer August 16, 2014 Why Pump Therapy? Mimics normal
Minimal Models for Glucose and Insulin Kinetics
Minimal Models for Glucose and Insulin Kinetics Daniel R. Kerner, PhD. Civilized Software, Inc. 12109 Heritage Park Circle Silver Spring MD 20906 Tel.: (301)-962-3711 email: [email protected] URL: www.civilized.com
Diabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke
Diabetes and Stroke Understanding the connection between diabetes and the increased risk of stroke Make the Connection Almost 26 million people in the U.S. roughly 8 percent of the population have diabetes.
CLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
CLOSED LOOP MODEL FOR GLUCOSE INSULIN REGULATION SYSTEM USING LABVIEW
CLOSED LOOP MODEL FOR GLUCOSE INSULIN REGULATION SYSTEM USING LABVIEW 1 P Srinivas 2 P.Durga Prasada Rao 1 Associate Professor, Department of EIE, VR Siddhartha Engineering College, Vijayawada, India Email:
The What, Why, Who & How of Insulin Pumps. Bridget Lydon May 2014
The What, Why, Who & How of Insulin Pumps Bridget Lydon May 2014 Topics WHAT is an insulin pump HOW a pump works WHY use a pump WHO should use a pump Pharmac criteria for funded pumps All began back in
Diabetic Emergencies. David Hill, D.O.
Diabetic Emergencies David Hill, D.O. Class Outline Diabetic emergency/glucometer training Identify the different signs of insulin shock Diabetic coma, and HHNK Participants will understand the treatment
Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES
Anneli, Martina s daughter In better control with her pump since 2011 MY CHILD HAS TYPE 1 DIABETES Many parents whose child is diagnosed with Type 1 diabetes wonder: Why is this happening to my child?
CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
See, Think, and Act! Diabetes
See, Think, and Act! Diabetes California After School Resource Center (CASRC) Administered for the California Department of Education (C.D.E.) Hello. My name is Joan Edelstein. I am a health trainer for
Nutrition. Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT
1 Nutrition Type 2 Diabetes: A Growing Challenge in the Healthcare Setting NAME OF STUDENT 2 Type 2 Diabetes: A Growing Challenge in the Healthcare Setting Introduction and background of type 2 diabetes:
Getting the Big Picture
About Diabetes This health information is being provided for general educational purposes only. Your health care provider is the single best source of information regarding your health. Please consult
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding
A Study on the Comparison of Electricity Forecasting Models: Korea and China
Communications for Statistical Applications and Methods 2015, Vol. 22, No. 6, 675 683 DOI: http://dx.doi.org/10.5351/csam.2015.22.6.675 Print ISSN 2287-7843 / Online ISSN 2383-4757 A Study on the Comparison
Diabetes and exercise
Diabetes and exercise Summary Symptoms of hypoglycaemia are caused by low blood sugar. Hypoglycaemia can occur if you take your diabetes medication and then do not eat enough or exercise more than usual.
Anchor Bay School District Diabetic Medical Care Plan. Student Name Date Grade Teacher
Rev: 4/2009 Anchor Bay School District Diabetic Medical Care Plan Place Child s Picture Here Student Name Date Grade Teacher Emergency Contact information (Please list in order to be called) #1 Parent
Taking Insulin Pumps to School. Rachel Calendo, MS, RN, CPNP, CDE, Martha Cuevas, RN, BSN, CPT
Taking Insulin Pumps to School Rachel Calendo, MS, RN, CPNP, CDE, Martha Cuevas, RN, BSN, CPT Insulin Pumps Today A micro-computer, about the size of a pager Programmed to deliver both a preset amount
Lab 2. Spectrophotometric Measurement of Glucose
Lab 2 Spectrophotometric Measurement of Glucose Objectives 1. Learn how to use a spectrophotometer. 2. Produce a glucose standard curve. 3. Perform a glucose assay. Safety Precautions Glucose Color Reagent
Challenges in Glycemic Control in Adult and Geriatric Patients. Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner
Challenges in Glycemic Control in Adult and Geriatric Patients Denyse Gallagher, APRN-BC, CDE Endocrinology Nurse Practitioner Provide an overview of diabetes prevalence; discuss challenges and barriers
Blood Glucose Management
Blood Glucose Management What Influences Blood Sugar Levels? There are three main things that influence your blood sugar: Nutrition Exercise Medication What Influences Blood Sugar Levels? NUTRITION 4 Meal
JDRF Type One Nation Research Summit Diabetes Technology: A Bridge to a Cure
JDRF Type One Nation Research Summit Diabetes Technology: A Bridge to a Cure Kelly L. Close, president, Close Concerns editor-in-chief, diatribe March 1, 2014 closeconcerns.com diatribe.org @diatribenews
BLOOD GLUCOSE MONITORING MEDICATION
DIABETES CARE FOR SCHOOL MEDICAL MANAGEMENT PLAN Most Recent A1C and Date: BLOOD GLUCOSE MONITORING Meter Type: Testing Independently: yes no Testing times: Before meals Two hours after insulin dosing
Continuous Subcutaneous Insulin Infusion (CSII)
IMPORTANCE OF FOCUS CSII (Insulin pumps) have been used for more than 35 years. In the U.S. in 2005, the level of insulin pump penetration was estimated at 20 to 30% in patients with type 1 diabetes mellitus
I. Research Proposal. 1. Background
Sample CFDR Research Proposal I. Research Proposal 1. Background Diabetes has been described as the the perfect epidemic afflicting an estimated 104 million people worldwide (1). By 2010, this figure is
The Family Library. Understanding Diabetes
The Family Library Understanding Diabetes What is Diabetes? Diabetes is caused when the body has a problem in making or using insulin. Insulin is a hormone secreted by the pancreas and is needed for the
